• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sponsors Must Repeat Studies Done by Troubled Indian CROs, FDA Cautions

Sponsors Must Repeat Studies Done by Troubled Indian CROs, FDA Cautions

October 4, 2021

In a rare move, the FDA has informed sponsors that used two Indian CROs with concerning data integrity practices that some studies those firms conducted will need to be repeated.

The FDA issued a public warning that it will not accept bioequivalence or bioavailability studies conducted by Synchron Research Services or Panexcell Clinical Lab, two Indian CROs that the agency identified as having troubling data integrity problems. The pair of companies have been around since 1998.

This sort of action against CROs is something rarely seen from the FDA; the last occurrence was in April 2016 and involved another Indian CRO, Semler Research.

An FDA review is currently underway to root out any potential safety issues and none have been identified thus far. The agency’s probes in this most recent case revealed significant instances of misconduct and regulatory violations that rendered the study data they submitted invalid. But also worrying is that the FDA took this long to take action against the CROs. The agency issued both firms untitled letters in 2019, outlining “significant objectionable conditions” it found during November 2019 inspections. “We do not make decisions lightly and do not rush to judgment,” an FDA spokesperson said in defending the two-year lag.

Both Panexcell’s and Synchron’s untitled letters describe “unusual and unexplainable study records” linked to concerning approaches that impacted the firms’ analytical methods. After review, the FDA determined that the study data the two companies submitted were falsified and unreliable. The names of the studies and sponsors affected by the data integrity problems were redacted from the letters.

Read the Panexcell letter here: https://bit.ly/3D2QJxZ.

Read the Synchron letter here: https://bit.ly/3F9bV7j.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing